News Merck MS tablet set for wider use by NHS in England Thousands more patients with multiple sclerosis in England will soon be able to access Merck KGaA's take-at-home tablet Mavenclad.
R&D Novartis’ Kesimpta, ECTRIMS 2022, and relapsing multiple scl... Having presented new data at last year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting – where the safety and efficacy of Novartis’ Kesimpta (
Oncology On the forefront of healthcare change, turning innovative sc... Claus Zieler, chief commercial and medical affairs officer & member of the Executive Committee at Astellas Pharma, spoke with pharmaphorum at ASCO25.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
